TAC-T Cells for Solid Tumors
Time: 3:30 pm
day: Day One
Details:
- Key advantages of T cells engineered with the TAC (T Cell Antigen Coupler) receptor to treat solid tumors
- Development status of TAC01-HER2, a HER2-directed TAC-T cell product in a Phase I clinical trial
- Identification and development of novel TAC receptors against safe solid tumor antigens
